SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001493152-23-007365
Filing Date
2023-03-13
Accepted
2023-03-13 09:00:11
Documents
14
Period of Report
2023-03-09
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 49659
2 ex99-1.htm EX-99.1 22971
3 ex99-1_001.jpg GRAPHIC 15019
  Complete submission text file 0001493152-23-007365.txt   271472

Data Files

Seq Description Document Type Size
4 INLINE XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT otlc-20230309.xsd EX-101.SCH 3230
5 INLINE XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT otlc-20230309_lab.xml EX-101.LAB 34240
6 INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT otlc-20230309_pre.xml EX-101.PRE 22361
8 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3289
Mailing Address 29397 AGOURA RD. #107 AGUORA HILLS CA 91301
Business Address 29397 AGOURA RD. #107 AGUORA HILLS CA 91301 650-635-7000
Oncotelic Therapeutics, Inc. (Filer) CIK: 0000908259 (see all company filings)

IRS No.: 133679168 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-21990 | Film No.: 23725894
SIC: 2834 Pharmaceutical Preparations